Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings, Inc. (SNCE) is frequently featured in clinical research news for its role in expanding patient access to trials through virtual and direct-to-patient models. Company announcements highlight its Metasite™ Virtual Site, Direct-to-Patient Site, and Patient Recruitment solutions, which are used by clinical trial sponsors and CROs to address enrollment and study conduct challenges across a range of therapeutic areas.
News about Science 37 often focuses on its participation in Phase 2 and Phase 3 studies, including rare disease, asthma, infectious disease, and immunocompromised patient cohorts. The company has reported contributing significant portions of total enrollment in pivotal trials, as well as helping under-enrolling studies trend back toward projected recruitment targets. These updates provide insight into how its decentralized and virtual site models function in real-world clinical programs.
Another recurring theme in Science 37 news is regulatory oversight and quality. The company has disclosed multiple FDA inspections of its Metasite™ and Direct-to-Patient Site models, with outcomes described as No Action Indicated and no Form 483s issued. Coverage of these inspections details how regulators have reviewed internal processes, technology platforms, data integrity, subject safety, and Principal Investigator oversight.
Investors and industry observers following SNCE news can expect updates on new partnerships with sponsors and service providers, case studies on enrollment performance, and developments related to its headquarters and operational footprint in Morrisville, North Carolina. This news stream offers context on how Science 37’s virtual and direct-to-patient approaches are being applied across different studies and therapeutic areas.
Science 37 (SNCE) completed its third FDA inspection with a No Action Indicated (NAI) recommendation on Oct 8, 2025, and no Form 483 issued. The inspection reviewed processes, platforms, data integrity, patient safety, protocol adherence, and PI oversight for a registrational Phase 3 primary biliary cholangitis study in which Science 37 enrolled 47% of the US study population.
This is the company's third consecutive NAI in under two years (prior NAI outcomes in March 2024 and April 2025), highlighting consistent regulatory compliance for its Direct-to-Patient Site, nationwide recruitment and 50-state medical licensure, and site services including investigator oversight and research-grade nursing.
Science 37 (NASDAQ:SNCE) and Catalent have announced a strategic partnership to revolutionize clinical trial accessibility through direct-to-patient delivery of investigational medicinal products (IMPs). The collaboration has demonstrated significant success across 17 studies, enrolling 1,700 patients with an average of 26% of total study populations through a single Direct-to-Patient Site.
The partnership has already facilitated over 6,400 shipments to study participants, achieving an enrollment rate of 9 patients per month - equivalent to more than 15 traditional brick-and-mortar locations. This integrated solution offers sponsors a streamlined approach with a single contract and budget, while expanding access to underserved populations.
Science 37 has successfully completed its second FDA inspection of its Direct-to-Patient Site, receiving a No Action Indicated (NAI) status with no Form 483 issued. The inspection focused on the company's participation in a Phase 3 asthma study, where Science 37 contributed 28% of total patient enrollment.
The FDA evaluation covered internal processes, technology, data integrity, patient safety, protocol adherence, Principal Investigator oversight, and documentation. This follows a previous successful FDA inspection in March 2024 that reviewed three pivotal Phase 3 trials.
Science 37's Direct-to-Patient Site enables clinical trial sponsors to reach 100% of target patient populations through home-based research, supported by investigators with 50-state medical licensure and research-grade nursing services.
Science 37 has appointed Tyler Van Horn as its new CEO, effective January 14, 2025. Van Horn, previously the Chief Commercial Officer, has played a key role in driving operational excellence and shaping strategic initiatives that prioritize client success, contributing significantly to the company's growth since he joined in 2021.
His tenure has seen the assembly of a team capable of matching or surpassing traditional clinical trial standards, with a focus on patient well-being and safety through at-home services. Van Horn emphasizes the importance of enabling therapies to reach their endpoints faster, gaining approval, and ensuring equitable health outcomes. He aims to support sponsors with world-class research teams and innovative solutions, particularly targeting underserved populations.
Van Horn's elevation to CEO is set to build on past successes while reinforcing the company's commitment to growth, innovation, and enhanced solution delivery. Science 37 continues to lead in patient access, diversity, and safety in clinical research.
Science 37 achieved significant success in a Phase 3 rare disease trial sponsored by GSK, contributing 17-47% of U.S. enrollment for a hepatology study focused on cholestatic pruritus in primary biliary cholangitis (PBC). The trial, requiring 230 global participants, utilized Science 37's Direct-to-Participant Site solution, enabling patients to participate from home and reducing travel burden. The approach proved highly effective, with 82.3% of participants completing Part A of the trial. Science 37's ability to screen across most U.S. states and facilitate at-home trial experiences helped overcome geographical barriers and maintain study continuity.
Science 37, a leader in enhancing patient access to clinical trials, has been awarded Frost & Sullivan's 2024 Global Company of the Year Award for Decentralized Clinical Trials. This prestigious honor recognizes Science 37's visionary innovation, market-leading performance, and unmatched customer care in the industry.
The award solidifies Science 37's growing influence in the clinical trial sector, which is increasingly turning to decentralization to overcome recruitment, enrollment, and retention challenges. Frost & Sullivan selected Science 37 after a rigorous analytical process considering multiple nominees and evaluating Best Practices criteria across two dimensions.
David Coman, CEO of Science 37, expressed deep honor in receiving this recognition, emphasizing the company's commitment to transforming the clinical trial process for the benefit of both patients and sponsors.
Science 37, a leader in enhancing patient access to clinical trials, has unveiled its new 19,000-square-foot corporate headquarters in Morrisville, North Carolina, within Research Triangle Park. This state-of-the-art facility will serve as a centralized hub for all Science 37 operations, fostering cross-functional collaboration and integrated solution delivery. The move is expected to improve the company's ability to support clinical trial sponsors with greater consistency, speed, and quality in patient recruitment and study conduct.
CEO David Coman emphasized that the relocation not only enhances their operational capabilities but also symbolizes Science 37's commitment to the region and to helping sponsors improve their probability of success in clinical trials. This strategic move reflects the company's recent growth and continued dedication to advancing clinical research accessibility.
Science 37, a leader in enhancing patient access to clinical trials, has reported significant success in its partnership with a biopharmaceutical company focused on infectious disease prevention research. For a Phase 3 trial involving immunocompromised patients, Science 37 utilized its proprietary Virtual Site and Patient Recruitment solutions to achieve remarkable results:
- Recruited and enrolled 129 patients across 36 states in just 8 weeks
- Averaged 65 patient enrollments per month
- Successfully randomized and treated 42% of the trial cohort
- Achieved significant geographic, socio-economic, and cultural diversity among participants
This achievement highlights Science 37's capability to meet challenging clinical trial demands while enhancing patient access and care for vulnerable populations in a fully decentralized manner.
Science 37 has significantly enhanced patient recruitment and enrollment in over 20 clinical trials that were underperforming. Their proprietary Virtual Site and Patient Recruitment solutions facilitated the identification, recruitment, medical qualification, and enrollment of patients without geographic limitations. This intervention has been effective in Phase 2 through Phase 4 and Observational trials across various therapeutic areas, including Hematology, Hepatology, Infectious Diseases, CNS, Oncology, and Rare Diseases. The company's Patient Recruitment service is available both independently and in combination with their Virtual Site, Metasite™, to accelerate patient access and improve trial outcomes.
Science 37 announced it has surpassed enrollment goals for a Phase 2 clinical trial of a small molecule therapeutic for Cholestatic Pruritus, enrolling 21% of study participants using its Metasite™ and Patient Recruitment solutions.
Over a 20-month period from September 2022 to April 2024, Science 37 achieved 11 times the average enrollment speed of traditional research sites, enrolling an average of 1 patient per month.
This success highlights Science 37's ability to recruit patients from broader geographical areas, enhancing the efficiency of rare disease research.
These services are available to clinical research sponsors and CROs either as standalone offerings or integrated with their Virtual Site solutions.
